OasisLMS

AUA2026 Spotlight: PARP-Inhibitor Combination Treatments for the Urologic Care Team addresses PARP-Inhibitors in the rapidly changing metastatic prostate cancer (mPC) landscape. 

 ACKNOWLEDGEMENTS
Support provided by independent educational grants from: 

• • Astrazeneca
  • Merck & Co., Inc
  • Pfizer, Inc.

• APPs
• Residents
• Fellows
• Young Urologists
• Urologists

At the conclusion of this CME activity, participants will be able to:

1. Integrate biomarker and genetic testing principles into clinical workflows for patients with metastatic prostate cancer, including when to order testing, how to interpret HRR mutation results (inclusive of BRCA and non-BRCA), and how to address barriers to testing through multidisciplinary coordination.
2. Explain the mechanism of action of PARP inhibitors and the biological and clinical rationale for their use—both as monotherapy and in combination approaches—in the treatment of mPC.
3. Evaluate emerging efficacy and safety data on PARPi combinations, including patient subgroup analyses, sequencing strategies, and the role of combination therapy in different stages of mPC.
4. Apply best practices for side effect monitoring and mitigation in patients receiving PARP inhibitors alone or in combination, leveraging the multidisciplinary team for optimal therapy management and patient quality of life.
5. Implement guideline-concordant care strategies in practice, including genetic testing workflow implementation, coordination among care team members, and patient engagement in shared decision-making and clinical trial enrollment.
6. Utilize current evidence-based guidelines to select and sequence PARP inhibitor therapy for patients with mPC, optimizing oncologic outcomes while individualizing care based on molecular profile and patient-specific factors.

AUA Office of Education Staff has nothing to disclose.

All relevant financial relationships have been mitigated.

AUA ACCREDITATION INFORMATION

Method of Participation: Learners will participate in this online educational activity by taking the pretest, viewing the online module and completing the posttest and evaluation. To claim CME credit for this enduring material, learners must complete the posttest, passing with 80% accuracy and submit the program evaluation.

Estimated time to complete this activity: 1.00 hours

Renew Date: May, 2026
Expiration Date: May, 2027

Accreditation: The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation: The American Urological Association designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Other Learners: The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit^TM.

Evidence Based Content: It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

AUA Disclosure Policy: All persons in a position to control the content of a CME activity are required to disclose to the AUA, as the ACCME-accredited provider, all financial relationships with any ineligible company (formerly commercial interests) during the previous 24 months. An ineligible company is defined as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The AUA must determine if the individuals relationships are relevant to the educational content and mitigate any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners with information so they can make their own judgments.

Mitigation of Identified Conflict of Interest: All disclosures will be reviewed by the AUA Conflict of Interest (COI) Review Work Group Chair and/or Vice Chair for identification of relevant financial relationships that result in conflicts of interest. The AUA COI Review Work Group, working with Office of Education staff, will document the mechanism(s) for management and mitigation of the conflict of interest and final approval of the activity will be documented prior to implementation.

Off-label or Unapproved Use of Drugs or Devices: The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.

AUA PARTICIPANT INFORMATION & POLICIES

Disclaimer: The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.

Reproduction Permission: Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the American Urological Association.